FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Baity Glenn						ACADIA PHARMACEUTICALS INC [ACAD]									all applic Directo Officer	cable) r (give title	g i ci30	10% Ow Other (s	ner
(Last) (First) (Middle) 3611 VALLEY CENTRE DRIVE, SUITE 300						3. Date of Earliest Transaction (Month/Day/Year) 11/10/2016									below) below) EVP AND GC				
(Street) SAN DIEGO CA 92130				_ 4. _	4. If Amendment, Date of Original Filed (Month/Day/Year)									ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5		(Zip) 	Non-Deri	ivativ	e Sec	urit	ies A	cquired,	Di	sposed o	f, or B	eneficia	ally (Owned				
1. Title of Security (Instr. 3) 2. Trans Date				2. Transac	tion	2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amou Securiti Benefici Owned		nt of es ally Following	Form:	: Direct 0 Indirect E str. 4) 0	7. Nature of Indirect Beneficial Ownership	
									Code V		Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	action(s)		[(Instr. 4)
Common Stock 11/10/201					2016	.6			М		10,200	A	\$1.5	5	73	73,121		D	
Common Stock 11/10/201				2016	16			S ⁽¹⁾		10,200	D	\$30.06	74 ⁽²⁾	62,921			D		
		•	Table								posed of, convertil				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, /Day/Year)	Date, Transa Code (6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Do	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amour or Numbe of Shares	er					
Stock Option (right to	\$1.55	11/10/2016			M			10,200	(3)		03/11/2020	Commo Stock	ⁿ 10,20	00	\$0	40,878	3	D	

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$30.00 to \$30.17 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- 3. 25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.

/s/ Glenn F. Baity

11/14/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.